Cost Of Revenue - Prostatype Genomics AB (STO:PROGEN) - Alpha Spread
P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 0.019 SEK -7.32% Market Closed
Market Cap: 18.8m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prostatype Genomics AB
Cost of Revenue Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Cost of Revenue
kr2.4m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cost of Revenue
-kr346.3m
CAGR 3-Years
-20%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cost of Revenue
-kr57.2m
CAGR 3-Years
-42%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cost of Revenue
-kr1.5B
CAGR 3-Years
-42%
CAGR 5-Years
-27%
CAGR 10-Years
-26%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cost of Revenue
-kr5.3B
CAGR 3-Years
-21%
CAGR 5-Years
-14%
CAGR 10-Years
-18%
BioArctic AB
STO:BIOA B
Cost of Revenue
-kr50.9m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Cost of Revenue?
Cost of Revenue
2.4m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Cost of Revenue amounts to 2.4m SEK.

What is Prostatype Genomics AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-10%

The average annual Cost of Revenue growth rates for Prostatype Genomics AB have been -10% over the past three years .

Back to Top